1-(4-methoxyphenyl)cyclopentanecarbonyl chloride | 63200-97-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(4-methoxyphenyl)cyclopentanecarbonyl chloride
• 英文别名: 1-(4-methoxyphenyl)cyclopentane-1-carbonyl chloride
• CAS: 63200-97-5
• 化学式: C₁₃H₁₅ClO₂
• 分子量: 238.714
• InChiKey: SJHUSIGZXTXFCP-UHFFFAOYSA-N

物化性质

• 熔点：
  55°C

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-methoxyphenyl)cyclopentanecarbonyl chloride 在 吡啶 、 4-二甲氨基吡啶 、 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 53.0h， 生成 (4S)-3-{[1-(4-methoxyphenyl)cyclopentyl]carbonyl}-1,3-thiazolidine-4-carboxylic acid
  参考文献：
  名称：

  EP3643703

  摘要：

  公开号：
• 作为产物：
  描述：

  1-(4-甲氧基苯基)-1-环戊烷甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-(4-methoxyphenyl)cyclopentanecarbonyl chloride
  参考文献：
  名称：

  钯 (II) 催化的 N-甲氧基酰胺和芳烃的 C(sp2)-H 键活化/C-N 键裂解环化

  摘要：

  开发了 Pd(II) 催化的 N-烷氧基酰胺芳烃的 C-H 键活化/C- N键裂解环化反应以合成 9,10-二氢菲酮衍生物。该反应表现出良好的官能团相容性，产率高达 92%。详细的机理研究表明，C-N键断裂的关键是形成的八元钯环中间体与羰基进行亲核加成，这为N-烷氧基酰胺定向C-H键活化提供了一种新的实用途径。

  DOI：

  10.1021/acs.orglett.2c00161

文献信息

• [EN] CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS<br/>[FR] COMPOSES D'ACIDE CARBAMIQUE COMPRENANT UNE LIAISON ESTER OU CETONE, UTILISES COMME INHIBITEURS DE L'HISTONE DESACETYLASE
  申请人：TOPOTARGET UK LTD

  公开号：WO2004065354A1

  公开（公告）日：2004-08-05

  This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently: -O-C(=O)- or -C(=O)-O- or - C(=O)-; Cy is a cyclyl group and is independently: C3-20carbocyclyl, C3-20heterocyclyl, or C5-20aryl; and is optionally substituted; Q1 is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted; Q2 is an acid leader group, and is independently: C1-8alkylene; and is optionally substituted; or: Q2 is an acid leader group, and is independently: C5-20arylene; C5-20arylene-C1-7alkylene; C1-7alkylene-C5-20arylene; or C1-7alkylene-C5-20arylene-C1-7alkylene; and is optionally substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC,and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  这项发明涉及某些具有以下式(I)的氨甲酸化合物，其抑制HDAC（组蛋白去乙酰化酶）活性：其中：J是一个连接的功能基团，独立地为：-O-C(=O)-或-C(=O)-O-或-C(=O)-；Cy是一个环烷基团，独立地为：C3-20碳环烷基、C3-20杂环烷基或C5-20芳基；并且可以选择性地被取代；Q1是一个环烷基领头基团，独立地是通过从具有4至7个环原子的饱和单环碳氢化合物的环碳原子中去除两个氢原子获得的双价双齿基团，或者通过从具有4至7个环原子，包括1个氮环原子或1个氧环原子的饱和单环杂环化合物的环碳原子中去除两个氢原子获得的双价双齿基团；并且可以选择性地被取代；Q2是一个酸领头基团，独立地为：C1-8烷基烯；并且可以选择性地被取代；或者：Q2是一个酸领头基团，独立地为：C5-20芳基烯；C5-20芳基烯-C1-7烷基烯；C1-7烷基烯-C5-20芳基烯；或C1-7烷基烯-C5-20芳基烯-C1-7烷基烯；并且可以选择性地被取代；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包括这种化合物的药物组合物，以及在体内外使用这种化合物和组合物来抑制HDAC，并用于治疗由HDAC介导的疾病、癌症、增殖性疾病、牛皮癣等。
• Novel 1-Phenylcycloalkanecarboxylic Acid Derivatives Are Potent and Selective .sigma.1 Ligands
  作者：Silvia N. Calderon、Sari Izenwasser、Brett Heller、J. Silvio Gutkind、Mariena V. Mattson、Tsung-Ping Su、Amy Hauck Newman

  DOI：10.1021/jm00041a006

  日期：1994.7

  series of carbetapentane analogs were prepared. Phenyl ring substitution; contraction, expansion, and replacement with a methyl group of the cyclopentyl ring; replacement of the carboxylate function with an amide, methyl ether, and methylamine; and replacement of the N,N-diethyl substituent with a morpholino or piperidino moiety were investigated. All of these novel analogs were evaluated for binding

  Carbetapentane（1-苯基-1-环戊烷羧酸1，2- [2-（2-（二乙基氨基）乙氧基]乙基]乙酯与sigma位高结合，是一种有效的镇咳药，抗惊厥药和痉挛药。然而，Carbetapentane也在毒蕈碱结合位点相互作用，目前尚不清楚这些受体系统中的任何一个是否参与了该药物的作用机制。为了确定这些精神活动是否可以归因于sigma位点的相互作用，制备了一系列的Carbetapentane类似物。苯环取代；收缩，膨胀和用环戊基环的甲基取代；用酰胺，甲醚和甲胺代替羧酸酯官能团；并且研究了用吗啉代或哌啶子基部分取代N，N-二乙基取代基。评估了所有这些新的类似物与sigma 1和sigma 2位点的结合，并比较了毒蕈碱m1和m2与PCP（1-（1-苯基环己基）哌啶）受体的结合。所有化合物对sigma 1的选择性都高于sigma 2的位置，三个选择性最高的类似物是化合物34（65倍），35（7
• Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring
  作者：Ryutaro Kanada、Yoshiko Kagoshima、Masayoshi Asano、Takashi Suzuki、Takeshi Murata、Makoto Haruta、Mizuki Takahashi、Osamu Ubukata、Kazuyuki Hashimoto、Kenichi Obata、Kawori Kihara、Mutsumi Kuroha、Toshihiro Banjo、Noriko Togashi、Kazumi Sato、Yuka Yamamoto、Kanae Suzuki、Takeshi Isoyama、Yuichi Tominaga、Saito Higuchi、Hiroyuki Naito

  DOI：10.1016/j.bmcl.2022.128726

  日期：2022.6

  EP300 and its paralog CBP play an important role in post-translational modification as histone acetyltransferases (HATs). EP300/CBP inhibition has been gaining attention as an anticancer treatment target in recent years. Herein, we describe the identification of a novel, highly selective EP300/CBP inhibitor, compound 11 (DS17701585), by scaffold hopping and structure-based optimization of a high-throughput

  EP300 及其旁系同源 CBP 作为组蛋白乙酰转移酶 (HAT) 在翻译后修饰中发挥重要作用。近年来，EP300/CBP抑制作为抗癌治疗靶点受到关注。在这里，我们描述了一种新型的、高选择性的 EP300/CBP 抑制剂化合物11 ( DS17701585 )，通过支架跳跃和基于结构的优化高通量筛选命中1。化合物11 ( DS17701585 ) 在人肺鳞状细胞癌细胞系 LK2 异种移植小鼠模型中显示出 SRY-box 转录因子 2 (SOX2) mRNA 表达的剂量依赖性抑制作用。
• Palladium(II)-Catalyzed C(sp²)–H Bond Activation/C–N Bond Cleavage Annulation of <i>N</i>-Methoxy Amides and Arynes
  作者：Xiu-Fen Cheng、Ting Yu、Yi Liu、Nan Wang、Zhenzhen Chen、Guang-Lu Zhang、Lili Tong、Bo Tang

  DOI：10.1021/acs.orglett.2c00161

  日期：2022.3.25

  The Pd(II)-catalyzed C–H bond activation/C–N bond cleavage annulation reaction of N-alkyoxyamide aryne is developed to synthesize 9,10-dihydrophenanthrenone derivatives. This reaction exhibited good functional group compatibility with yields up to 92%. Detailed mechanistic studies showed that the key to C–N bond cleavage is the formed eight-membered palladacycle intermediate undergoing nucleophilic

  开发了 Pd(II) 催化的 N-烷氧基酰胺芳烃的 C-H 键活化/C- N键裂解环化反应以合成 9,10-二氢菲酮衍生物。该反应表现出良好的官能团相容性，产率高达 92%。详细的机理研究表明，C-N键断裂的关键是形成的八元钯环中间体与羰基进行亲核加成，这为N-烷氧基酰胺定向C-H键活化提供了一种新的实用途径。
• Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
  申请人：Finn W Paul

  公开号：US20060058282A1

  公开（公告）日：2006-03-16

  This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently: —O—C(═O)— or —C(═O)—O— or —C(═O)—; Cy is a cyclyl group and is independently: C 3-20 carbocyclyl, C 3-20 heterocyclyl, or C 5-20 aryl; and is optionally substituted; Q 1 is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted; Q 2 is an acid leader group, and is independently: C 1-8 alkylene; and is optionally substituted; or: Q 2 is an acid leader group, and is independently: C 5-20 arylene; C 5-20 arylene-C 1-7 alkylene; C 1-7 alkylene-C 5-20 arylene; or C 1-7 alkylene-C 5-20 arylene-C 1-7 alkylene; and is optionally substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  该发明涉及一类具有以下式子(I)的碳酰胺化合物，其抑制HDAC（组蛋白去乙酰化酶）活性：其中：J是连接功能基团，独立地为：—O—C(═O)—或—C(═O)—O—或—C(═O)—；Cy是环基团，独立地为：C3-20碳环基、C3-20杂环基或C5-20芳基；并且可以选择性地被取代；Q1是环基领导基团，独立地为从具有4至7个环原子的饱和单环烃或包括1个氮环原子或1个氧环原子的饱和单环杂环化合物的环碳原子上去除两个氢原子而得到的二价双齿基团；并且可以选择性地被取代；Q2是酸基领导基团，独立地为：C1-8烷基；并且可以选择性地被取代；或：Q2是酸基领导基团，独立地为：C5-20芳基、C5-20芳基-C1-7烷基、C1-7烷基-C5-20芳基或C1-7烷基-C5-20芳基-C1-7烷基；并且可以选择性地被取代；以及其药学上可接受的盐、溶剂化物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这样的化合物的制药组合物，以及这样的化合物和组合物的使用，无论是在体外还是体内，用于抑制HDAC，以及用于治疗由HDAC介导的疾病，如癌症、增生性疾病、牛皮癣等。